LKH Bregenz
- Address
- Carl-Pedenz-Straße 2, 6900 Bregenz, Austria
LKH Bregenz - Pediatric Rheumatology Research
LKH Bregenz is actively engaged in advancing pediatric rheumatology research, with a particular emphasis on improving treatment outcomes for children and adolescents with chronic inflammatory joint conditions. The center participates in international collaborative studies evaluating novel therapeutic approaches for young patients with complex autoimmune disorders.
- Juvenile Idiopathic Arthritis treatment and management
- Novel immunomodulatory therapies in pediatric populations
- Safety and efficacy studies in children aged 1 to 17 years
The research team at LKH Bregenz specializes in evaluating biologic and targeted synthetic disease-modifying antirheumatic drugs for pediatric conditions. Their participation in studies such as JUVE-X demonstrates commitment to expanding therapeutic options for children with juvenile idiopathic arthritis, contributing valuable data on safety profiles and treatment effectiveness in younger patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Eli Lilly & Co.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in LKH Bregenz
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Long-Term Safety and Efficacy of Baricitinib in Pediatric Patients with Juvenile Idiopathic Arthritis: A Phase 3 Multicenter Study | Eli Lilly & Co. | Phase III | Recruiting | Sep 2019 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Baricitinib | 1 | Unknown | 2019-09-10 | 2019-09-10 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.